GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005110019 | Oral cavity | OSCC | negative regulation of binding | 87/7305 | 162/18723 | 1.00e-04 | 7.54e-04 | 87 |
GO:19021173 | Oral cavity | OSCC | positive regulation of organelle assembly | 41/7305 | 67/18723 | 1.94e-04 | 1.30e-03 | 41 |
GO:20007852 | Oral cavity | OSCC | regulation of autophagosome assembly | 26/7305 | 39/18723 | 4.33e-04 | 2.63e-03 | 26 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
GO:01400566 | Oral cavity | OSCC | organelle localization by membrane tethering | 43/7305 | 77/18723 | 2.00e-03 | 9.28e-03 | 43 |
GO:0090141 | Oral cavity | OSCC | positive regulation of mitochondrial fission | 15/7305 | 21/18723 | 2.65e-03 | 1.16e-02 | 15 |
GO:19012642 | Oral cavity | OSCC | carbohydrate derivative transport | 44/7305 | 80/18723 | 2.67e-03 | 1.16e-02 | 44 |
GO:009875418 | Oral cavity | OSCC | detoxification | 75/7305 | 152/18723 | 5.99e-03 | 2.28e-02 | 75 |
GO:00440903 | Oral cavity | OSCC | positive regulation of vacuole organization | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
GO:00465788 | Oral cavity | OSCC | regulation of Ras protein signal transduction | 90/7305 | 189/18723 | 9.58e-03 | 3.40e-02 | 90 |
GO:00002661 | Oral cavity | OSCC | mitochondrial fission | 24/7305 | 42/18723 | 1.30e-02 | 4.34e-02 | 24 |
GO:001623615 | Oral cavity | LP | macroautophagy | 135/4623 | 291/18723 | 4.71e-16 | 6.70e-14 | 135 |
GO:001050615 | Oral cavity | LP | regulation of autophagy | 132/4623 | 317/18723 | 1.82e-11 | 1.28e-09 | 132 |
GO:0009896110 | Oral cavity | LP | positive regulation of catabolic process | 187/4623 | 492/18723 | 2.30e-11 | 1.58e-09 | 187 |
GO:0031331110 | Oral cavity | LP | positive regulation of cellular catabolic process | 163/4623 | 427/18723 | 3.03e-10 | 1.59e-08 | 163 |
GO:0043254110 | Oral cavity | LP | regulation of protein-containing complex assembly | 163/4623 | 428/18723 | 3.72e-10 | 1.92e-08 | 163 |
GO:0051098110 | Oral cavity | LP | regulation of binding | 140/4623 | 363/18723 | 2.47e-09 | 1.10e-07 | 140 |
GO:000703313 | Oral cavity | LP | vacuole organization | 79/4623 | 180/18723 | 1.26e-08 | 4.74e-07 | 79 |
GO:0071496110 | Oral cavity | LP | cellular response to external stimulus | 124/4623 | 320/18723 | 1.44e-08 | 5.36e-07 | 124 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALB | SNV | Missense_Mutation | novel | c.247N>A | p.Ala83Thr | p.A83T | P02768 | protein_coding | tolerated(0.06) | benign(0.068) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ALB | SNV | Missense_Mutation | novel | c.1814N>T | p.Ala605Val | p.A605V | P02768 | protein_coding | deleterious(0.02) | benign(0.041) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ALB | SNV | Missense_Mutation | | c.29N>A | p.Leu10His | p.L10H | P02768 | protein_coding | deleterious(0) | possibly_damaging(0.867) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALB | SNV | Missense_Mutation | | c.1802N>T | p.Ala601Val | p.A601V | P02768 | protein_coding | tolerated(0.53) | benign(0) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALB | insertion | Nonsense_Mutation | novel | c.75_76insTCTACTTATTGAAAGAGAGAAAGGAAAAAAATATGAAACAG | p.Ala26SerfsTer4 | p.A26Sfs*4 | P02768 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ALB | insertion | Nonsense_Mutation | novel | c.806_807insAGCATGGAGTAACTCCATAGGCCAACA | p.Cys269delinsTer | p.C269delins* | P02768 | protein_coding | | | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ALB | SNV | Missense_Mutation | | c.1249N>A | p.Glu417Lys | p.E417K | P02768 | protein_coding | deleterious(0.01) | possibly_damaging(0.476) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ALB | SNV | Missense_Mutation | rs267600248 | c.628C>T | p.Arg210Trp | p.R210W | P02768 | protein_coding | deleterious(0.01) | possibly_damaging(0.883) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ALB | SNV | Missense_Mutation | rs774294755 | c.881N>T | p.Ser294Leu | p.S294L | P02768 | protein_coding | tolerated(0.31) | benign(0.041) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ALB | SNV | Missense_Mutation | rs150388973 | c.946N>A | p.Glu316Lys | p.E316K | P02768 | protein_coding | tolerated(0.07) | benign(0.109) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | Sodium lauryl sulfate | | |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | Gadofosveset | GADOFOSVESET | |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | RALTITREXED | RALTITREXED | 15025739 |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | Activated recombinant FVII-albumin fusion protein | | |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | Oxyphenbutazone | OXYPHENBUTAZONE | |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | EPIGALOCATECHIN GALLATE | EPIGALOCATECHIN GALLATE | 20598557 |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | PHENYLBUTAZONE | PHENYLBUTAZONE | 20869876 |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | EPIGALLOCATECHIN | EPIGALLOCATECHIN | 20598557 |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | Iodipamide | IODIPAMIDE | |
213 | ALB | TRANSPORTER, DRUGGABLE GENOME | | [19F]-HALOPERIDOL | [19F]-HALOPERIDOL | |